

**BIOGRAPHICAL SKETCH**

<b>NAME</b> Pablo Cure	<b>CURRENT POSITION TITLE</b> Innovation Manager, Clinical Trials and Industry Relations Specialist
---------------------------	--------------------------------------------------------------------------------------------------------

**CONTACT INFORMATION**

Home Address: 601 WILKES ST #303, ALEXANDRIA, VA 22314

Cell phone: 305-200-9744

Email: [dr\\_pablocure@hotmail.com](mailto:dr_pablocure@hotmail.com) or [pcure@childrensnational.org](mailto:pcure@childrensnational.org)**EDUCATION/TRAINING**

<b>INSTITUTION AND LOCATION</b>	<b>DEGREE</b> (if applicable)	<b>YEAR(S)</b>	<b>FIELD OF STUDY</b>
Colegio Sagrado Corazón Barranquilla-Colombia	High School	1995	High School
Universidad del Norte Barranquilla-Colombia	MD	1996 – 2003	Doctor in Medicine
University of Miami School of Medicine, Miami, FL, USA	International Observer	2002 – 2003	Medical Rotations Observership
University of Miami School of Medicine, Diabetes Research Institute, Miami, FL, USA	Postdoctoral Fellow	2004 – 2008	Diabetes/Islet Transplantation
The George Washington University, Washington, DC, USA	Masters of Public Health	2008 – 2010	Public Health- Epidemiology/Biostatistics
Children's National Medical Center, Washington, DC, USA	MPH Practicum Project	2009	Endocrinology & Diabetes
Children's National Medical Center, Washington, DC, USA	LEAP Scholar	2010 – 2011	Innovation & Product Development

**A. Positions and Honors****Positions and Employment**

- 2010 – Present Innovation Manager, Clinical Trials and Industry Relations Specialist & LEAP Scholar, Office of Innovation Development and Investigational Therapeutics, Children's National Medical Center, Washington, DC
- 2004 – 2008 Postdoctoral Fellow & Senior Research Coordinator, Diabetes Research Institute, University of Miami School of Medicine, Miami, FL

**Other Experience and Professional Memberships**

- 2011 – American Academy of Pediatrics – PS-Advanced Therap. and Technology - Member
- 2010 – Certified Clinical Research Professional (SOCRA)
- 2010 – Drug Information Association (DIA) – Member
- 2010 – Society of Clinical Research Associates (SOCRA) – Member
- 2009 – 2010 American Public Health Association – Member
- 2008 Good Clinical Practices Training, University of Miami School of Medicine
- 2008 Good Research Practices Certificate, University of Miami School of Medicine
- 2004 – CITI Human Subjects Research Educational Program

**Honors**

- 2010 Travel Grant Support from NICHD for Pediatric Pharmacogenomics and Personalized Medicine Conference, Children's Mercy Hospital, Kansas City, MO, USA
- 2008 Award of Excellence, Diabetes Research Institute, University of Miami School of Medicine, Miami, FL, USA
- 2005 Travel Grand Award, International Pancreas and Islet Transplant Association, Geneva, Switzerland
- 2003 Travel Grant Award, International Bone and Mineral Society and Japanese Society for

- 2002 Bone and Mineral Research, Osaka, Japan  
Gunter Fromm Best Clinical Study, Osteology and Mineral Metabolism Society, Buenos Aires, Argentina
- 2002 Aurelio Rapado Best Study Award, International Osteoporosis Foundation, Islas Margarita, Venezuela

## B. Publications, Original and Peer-reviewed

### Journals

1. Cure-Cure C, **Cure P**. Osteoporos Int. 2011 Sep 10. Validation of cross-sectional studies with long-term longitudinal studies [Epub ahead of print]. [PubMed](#)
2. **Cure P**, Cure-Cure C. Adolescent BMI and risk of diabetes versus coronary disease. N Engl J Med. 2011 Jun 30; 364 (26):2558 – 9. [PubMed](#)
3. Connor E, **Cure P**. “Creating hope” and other incentives for drug development for children. Sci Transl Med. 2011 Jan 19; 3 (66): 66cm1. [PubMed](#)
4. Leitão CB, Bernetti K, Tharavanij T, **Cure P**, Lauriola V, Berggren PO, Ricordi C, Alejandro R. Lipotoxicity and Decreased Islet Graft Survival. Diabetes Care. 2010 Mar; 33(3):658 – 60. [PubMed](#)
5. Leitão CB, Froud T, **Cure P**, Tharavanij T, Pileggi A, Ricordi C, Alejandro R. Non-albumin Proteinuria in Islet Transplant Recipients. Cell Transplant. 2010; 19 (1):119 – 25. [PubMed](#)
6. 2007 update on allogeneic islet transplantation from the Collaborative Islet Transplant Registry (CITR). CITR Research Group. Cell Transplant. 2009; 18(7): 753-67. [PubMed](#)
7. Tharavanij T, Froud T, Leitao CB, Baidal DA, Paz-Pabon CN, Shari M, **Cure P**, Bernetti K, Ricordi C, Alejandro R. Clinical use of fructosamine in islet transplantation. Cell Transplant. 2009;18(4):453-8. [PubMed](#)
8. Leitão CB, Bernetti K, Tharavanij T, **Cure P**, Ricordi C, Alejandro R: Type 2 Diabetes Mellitus Phenotype and Graft Survival after Islet Transplantation. Transplantation. 2009 Jul 15;88(1):57-61. [PubMed](#)
9. Leitão CB, **Cure P**, Messinger S, Pileggi A, Lenz O, Froud T, Faradji RN, Selvaggi G, Kupin W, Ricordi C, Alejandro R: Stable renal function after islet transplantation: importance of patient selection and aggressive clinical management. Transplantation 2009 Mar 15;87(5):681-8. [PubMed](#)
10. Alejandro R, Barton FB, Hering BJ, Wease S; Collaborative Islet Transplant Registry Investigators. Transplantation 2009 Dec 27;86(12):1783-8. [PubMed](#)
11. Froud T, Baidal DA, Faradji R, **Cure P**, Mineo D, Selvaggi G, Kenyon NS, Ricordi C, Alejandro R: Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation 2008 Dec 27;86(12):1695-701. [PubMed](#)
12. Faradji RN, Tharavanij T, Messinger S, Froud T, Pileggi A, Monroy K, Mineo D, Baidal DA, **Cure P**, Ponte G, Mendez AJ, Selvaggi G, Ricordi C, Alejandro R: Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation 2008 Dec 27;86(12):1658-65. [PubMed](#)
13. **Cure P**, Froud T, Leitão CB, Pileggi A, Tharavanij T, Bernetti K, Baidal DA, Selvaggi G, Ricordi C, Alejandro R: Late Epstein Barr virus reactivation in islet after kidney Transplantation 2008 Nov 15;86(9):1324-5. [PubMed](#)
14. Tharavanij T, Betancourt A, Messinger S, **Cure P**, Leitao CB, Baidal DA, Froud T, Ricordi C, Alejandro R: Improved long-term health-related quality of life after islet transplantation. Transplantation 2008 Nov 15;86(9):1161-7. [PubMed](#)
15. Leitão CB, Tharavanij T, **Cure P**, Pileggi A, Baidal DA, Ricordi C, Alejandro R: Restoration of Hypoglycemia Awareness after Islet Transplantation. Diabetes Care. 2008 Nov; 31(11):2114-5. [PubMed](#)

16. Leitaó CB, Cure P, Tharavanij T, Baidal DA, Alejandro R: Current challenges in islet transplantation. *Curr Diab Rep.* 2008 Aug;8(4):324-31. [PubMed](#)
17. Froud T, Faradji RN, Pileggi A, Messinger S, Baidal DA, Ponte GM, **Cure P**, Monroy K, Mendez A, Selvaggi G, Ricordi C, Alejandro R: The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy, and Metabolic Effects. *Transplantation.* 2008 Jul 15; 86(1):36-45. [PubMed](#)
18. Capozza RF, Cure-Cure C, COUNTRY GR, Meta M, **Cure P**, Rittweger J, Ferretti JL: Association between low lean body mass and osteoporotic fractures after menopause. *Menopause.* 2008 May 26. [PubMed](#)
19. **Cure P**, Pileggi A, Alejandro R: Exenatide and rare adverse events. *N Engl J Med* 2008 May 1; 358(18):1969-70. [PubMed](#)
20. **Cure P**, Pileggi A, Froud T, Messinger S, Faradji RN, Baidal DA, Cardani R, Curry A, Poggioli R, Pugliese A, Betancourt A, Esquenazi V, Ciancio G, Selvaggi G, Burke 3rd GW, Ricordi C, Alejandro R: Improved metabolic control and quality of life in seven patients with Type 1 diabetes following Islet After Kidney Transplantation. *Transplantation* 2008 Mar 27; 85(6):801-12. [PubMed](#)
21. Poggioli R, Enfield G, Messinger S, Faradji RN, Tharavanij T, Pisani L, **Cure P**, Ponte G, Baidal D, Froud T, Ricordi C and Alejandro R: Nutritional Status and Behavior in Subjects With Type] Diabetes, Before and After Islet Transplantation. *Transplantation* 2008; 85, (4):501-6. [PubMed](#)
22. Capozza RF, Cure-Cure C, COUNTRY GR, Meta M, **Cure P**, Rittweger J, Ferretti JL. Association between low lean body mass and osteoporotic fractures after menopause. *Menopause.* 2008 Sep-Oct; 15(5):905-13. [PubMed](#)
23. Ponte GM, Baidal DA, Romanelli P, Faradji RN, Poggioli R, **Cure P**, Froud T, Selvaggi G, Pileggi A, Ricordi C and Alejandro R: Resolution of severe atopic dermatitis after tacrolimus withdrawal. *Cell Transplant.* 2007;16(1):23-30. [PubMed](#)
24. Froud T, Faradji RN, Gorn L, Monroy K, Paz C, Baidal DA, Ponte G, **Cure P**, Poggioli R, Pileggi A, Ricordi C, Alejandro R: Dapsone-Induced Artifactual A1c Reduction in Islet Transplant Recipients. *Transplantation* 2007;83(6):824-5. [PubMed](#)
25. Faradji RN, Monroy K, Riefkohl A, Lozano L, Gorn L, Froud T, **Cure P**, Baidal D, Ponte G, Messinger S, Mastrototaro J, Ricordi C, Alejandro R: Continuous glucose monitoring system for early detection of graft dysfunction in allogeneic islet transplant recipients. *Transplant Proc.* 2006 Dec;38(10):3274-6. [PubMed](#)
26. Faradji RN, Monroy K, Messinger S, Pileggi A, Froud T, Baidal DA, **Cure P**, Ricordi C, Luzi L, Alejandro R: Simple measures to assess and monitor beta-cell mass and function after islet transplantation. *Am J Transplant* 2007;7(2):303-8. [PubMed](#)
27. **Cure P**, Pileggi A, Faradji RN, Baidal DA, Froud T, Selvaggi G, Ricordi C, Alejandro R: Cytomegalovirus infection in a recipient of solitary allogeneic islets. *Am J Transplant.* 2006; 6(5 Pt 1):1089-90. [PubMed](#)
28. Cure Cure C, **Cure P**: Bone mineral density and risk of fractures in grand multiparous. *Colombian Journal of Osteology and Mineral Metabolism.* 2005 Dec;4 (2):69 - 73.
29. Hafiz MM, Faradji RN, Froud T, Pileggi A, Baidal DA, **Cure P**, Ponte G, Poggioli R, Cornejo A, Messinger S, Ricordi C, and Alejandro R: Immunosuppression and Procedure Related Complications in 26 Patients with Type 1 Diabetes Mellitus Receiving Allogeneic Islet Cell. *Transplantation* 2005 Dec 27;80(12):1718-28. [PubMed](#)
30. Faradji RN, Monroy K, **Cure P**, Froud T, Baidal DA, Pileggi A, Messinger S, Ricordi C and Alejandro R: C-Peptide and glucose values in the peritransplant period after intraportal islet infusions in type 1 diabetes. *Transplant Proc.* 2005 Oct; 37(8):3433-4. [PubMed](#)
31. Cure-Cure C, Capozza RF, COUNTRY GR, Meta M, **Cure P** and Ferretti JL: Reference charts for the relationships between dual-energy X-ray absorptiometry -assessed bone mineral content and lean mass in 3,063 healthy men an premenopausal and postmenopausal women. *Osteoporos Int.* 2005Dec; 16(12):2095-106. [PubMed](#)

32. Froud T, Ricordi C, Baidal DA, Hafiz MM, Ponte G, **Cure P**, Pileggi A, Poggioli R, Ichii H, Khan A, Ferreira JV, Pugliese A, Esquenazi VV, Kenyon NS and Alejandro R: Islet Transplantation in Type 1 Diabetes Mellitus Using Cultured Islets & Steroid Free Immunosuppression: Miami Experience. Am J Transplant 2005; 5(8):2037-46. [PubMed](#)
33. **Cure P**, Pileggi A, Froud T, Norris PM, Baidal DA, Cornejo A, Hafiz MM, Ponte G, Poggioli R, Yu J, Saab A, Selvaggi G, Ricordi C and Alejandro R: Alterations of the Female Reproductive System in Recipients of Islet Grafts. Transplantation 2004 Dec 15;78(11):1576-81. [PubMed](#)
34. Capozza RF, COUNTRY GR, **Cure P**, Ferretti JL, Cure-Cure C: DEXA Study of Muscle-Bone Relationships in the Whole Body and Limbs of 2,512 Normal Men and Pre and Post-menopausal Women. Bone, 2004;35(1):283-95. [PubMed](#)
35. Cure Cure C, **Cure P**: Densidad Mineral Osea en Grandes Multiparas. Sociedad Iberoamericana de Informacion Cientifica. Expertos Invitados. 2004-08-14.
36. Cure Cure C, **Cure P**, Padilla Drago L, Penaranda J C: Frecuencia de Fracturas de Acuerdo al Sitio y su Relación con la edad en Mujeres Posmenopausicas. Rev. Colomb. Osteol. Metab Miner. 2004 ;3:27-31.21.
37. Cure Cure C, **Cure P**, Teran E, Lopez Jaramillo P: Bone mass Peak in multiparity and reduced risk of bone fractures in menopause. Int J of Gynecol and Obstet 2002; 76(3): 285-291. [PubMed](#)
38. Cure Cure Carlos, **Cure P**: Hormone replacement therapy and bone protection in multiparity: When to initiate it? American Journal of Obstetrics and Gynecology. 2001; 184: 580 - 3. [PubMed](#)
39. Cure Cure, **Cure P.**, Lopez Jaramillo P: Osteoporosis, Pregnancy and lactation. The Lancet 1998; 352 (9135): 1227-1228. [PubMed](#)
40. Cure Cure C, **Cure P**, Teran E, Lopez Jaramillo P: Bone mass Peak in multiparity and bone protection in menopause. Menopause Digest. 2002.
41. Cure Cure Carlos, **Cure P**: Densidad Mineral Osea y Frecuencia de Osteopenia y de Osteoporosis de acuerdo con la edad en mujeres mayores de 50 anos en la ciudad de Barranquilla. Acta Medica Colombiana. 2000: 25: 6 – 11
42. Cure Cure Carlos, **Cure P**: Distribution by age, gender and diagnosis of diabetes age in an endocrinology practice from January 1980 to December 1999 in Barranquilla Colombia. Unimetro 13. 2001; 24

#### Book Chapters

1. Faradji RN, **Cure P**, Ricordi C, and Alejandro R. Chapter: Care of the Transplant Recipient-Immunosuppressive Management and Complications. Book title: Islet Transplantation and beta cell replacement therapy by A.M. James Shapiro (Editor) and James A.M. Shaw (Editor). Publisher: Informa Healthcare; 1 edition (July 25, 2007). [Book](#)

#### C. Training/Grant Support

PNC Foundation supported The Laboratory for Entrepreneurial Achievement in Pediatrics (LEAP)

02/2010 – 02/2012

Role: LEAP Program Scholar

#### D. Computer Skills

PC Operating Systems, Microsoft Office, Outlook, SharePoint, Internet, Familiar with statistical software including SPSS and SAS.

#### E. Volunteering

**BioGeneius Challenge**, 06/11 - Present

International BioGeneius Challenge Judge, Full day, once a year.

Supervisor: Bianca Blanks (202) 312-9292

Evaluation and selection of best innovative ideas/projects presented by high school students from the USA and abroad at an International science competition sponsored by the Biotechnology Institute. Winners get cash prizes and the opportunity to visit the President at the White House.

**Disabilities Awareness Network (DAN), 2006, 2007**

Invited speaker, Full day, once a year.

Supervisor: Tatiana Garcia (786) 322-9774

Participate as invited speaker of two DAN annual events to help raise awareness about obesity, diabetes and metabolic diseases in at risk populations.